Navigation Links
Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements
Date:5/24/2013

NEW YORK, May 24, 2013 /PRNewswire/ -- In accordance with Rule 17.1 and Rule 2.9 of the Irish Takeover Rules and Rule 14e-1 of the United States Exchange Act, Echo Pharma Acquisition Limited ("Royalty Pharma") today announced acceptance levels its original offer for Elan Corporation (NYSE: ELN).

Background

On 2 May 2013, Echo Pharma Acquisition Limited ("Royalty Pharma") made an offer for the entire of the issued and to be issued share capital of Elan Corporation, plc ("Elan") (the "Original Offer"). 

On 20 May 2013, Royalty Pharma announced the terms of a revision to the Original Offer (the "Increased Offer"). The Increased Offer was made on 23 May 2013 and is an all cash offer of US$12.50 per Elan Share (including each Elan Share represented by an Elan ADS). The full terms of, and conditions to, the Increased Offer and the procedure for acceptance are set out in the revised offer document despatched by Royalty Pharma on 23 May 2013 (the "Revised Offer Document"). 

A reference in this announcement to the "Offer" means the Original Offer (including where the context so requires, any subsequent revision, variation, extension or renewal of the Original Offer, including in connection with the Increased Offer). Capitalised terms used but not defined in this announcement shall have the meaning given to them in the Revised Offer Document.

Royalty Pharma is making this announcement in accordance with Rule 17.1 and Rule 2.9 of the Irish Takeover Rules and Rule 14e-1 of the US Exchange Act.

Level of Acceptances

As at 1:00 p.m. (Irish time) / 8:00 a.m. (New York City time) on 23 May 2013 (being the date the Original Offer was revised), Royalty Pharma had received valid acceptances of the Offer (which had not been withdrawn) from Elan Stockholders in respect of 67,814 Elan Shares (including Elan Shares represented by Elan ADSs). These acceptances represent, at th
'/>"/>

SOURCE Royalty Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share
2. Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash
3. Selexis SA Sells Rights to Royalty Payments for More Than 15 Biologic Development Programs to Ligand Pharmaceuticals
4. PDL BioPharma Completes Structured Financing and Royalty Transaction with Avinger
5. Royalty Rates for Pharmaceuticals & Biotechnology: Real-Deal Information for Hundreds of Transactions
6. PDL BioPharma Provides First Quarter 2013 Royalty Revenue Guidance of $92 Million
7. Royalty Pharma Announces Proposal To Acquire Elan
8. Royalty Rates Take Center Stage in Biopharma Dealmaking
9. Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland
10. Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients
11. Intercept Pharmaceuticals to Present at Deutsche Bank Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Sciences, Inc. (NASDAQ: ALIM ) ("Alimera"), a ... commercialization of prescription ophthalmic pharmaceuticals, today announced that it ... financial results after the market close on Thursday, August ... the same day at 4:30 p.m. ET. ... Dan Myers , President and Chief Executive Officer, and ...
(Date:7/24/2014)... RALEIGH-DURHAM, N.C. , July 24, 2014 /PRNewswire/ ... company has signed an Agreement with Kineticos, a ... sciences consulting company. Kineticos will support LSI Medience ... in sepsis management, to demonstrate utility in clinical ... has shown potential utility in diagnosis of sepsis, ...
(Date:7/24/2014)... -- Perrigo Company (NYSE: PRGO ; TASE) today ... rating from the U.S. Food and Drug Administration (FDA) ... testosterone gel 1.0%. FDA concluded that Perrigo,s testosterone product ... be substituted with the full expectation that it will ... AndroGel 1% when used under the conditions specified in ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter 2014 Results 2LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3
(Date:7/24/2014)... Newark, NJ (PRWEB) July 24, 2014 ... which will give one lucky family a rent-free week ... only until August 3, 2014. Don’t miss your chance ... The sweepstakes is open to all New Jersey residents, ... Horizon BCBSNJ Facebook page, http://www.facebook.com/HorizonBCBSNJ . , ...
(Date:7/24/2014)... Memantine was initially developed by Merz to treat ... the brand name Akatinol; it was later licensed to Lundbeck ... the USA to Forest Labs as Namenda. Lundbeck reported the ... the US, Forest reported Namenda sales of USD 1.5 billion ... and the European region has increased the competition from generic ...
(Date:7/24/2014)... In signing the Workforce Innovation and ... Atlanta BeltLine Workforce Partnership in Healthcare as one ... ( http://www.whitehouse.gov/ready-to-work ). The Administration called for ... economic strategy and profiled successful local efforts to ... Obama highlights the power of partnerships in Atlanta,” ...
(Date:7/24/2014)... July 24, 2014 As the age ... to egg freezing as a way to ensure future ... otherwise decline with advancing reproductive age. Vitrification technology, a ... cutting edge medical technology that allows a woman to ... peak fertility years, which are then stored for future ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Members of the ... Wolnerman, RPh, CCIM, Senior Associate of Sales at OutcomesMTM, as ... appointed him to the Board and that his peers chose ... want to provide the best I can for the citizens ... am uniquely positioned to provide a special insight to concerns ...
Breaking Medicine News(10 mins):Health News:(Beach) Sands of Time Running out to Enter Horizon Blue Cross Blue Shield of New Jersey’s 2014 “Back to the Boardwalk” Sweepstakes 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 3Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 3Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 4Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 5Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 2Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 3Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 4Health News:Wolnerman Re-elected as Chairperson of Iowa State Board of Health 2
... radiation retinopathy who were destined to go blind within ... localized treatment with Avastin , a well-known cancer drug, ... 2007 Archives of Ophthalmology. ,This is a major ... radiation therapy and commonly develop radiation retinopathy, said Paul ...
... potentially lethal H5N1 strain of bird flu was confirmed this ... ,"All the turkeys on the farm have been killed and ... area, around 1,000 birds in all," Czech veterinary services spokesman ... (Friday)," he added. ,The H5N1 strain of bird flu ...
... people in Vietnam in the first six months of the ... period last year, the health ministry said Friday. ... 15 percent rise to 19,144 new infections from the mosquito-borne ... delta. ,Malaysia and other Southeast Asian countries have ...
... Researchers have formed a new compound AN2690, that might ... blocking an enzyme crucial for the protein synthesis of ... a team of researchers including Dickon Alley and Stephen ... Molecular Biology Laboratory (EMBL) outstation in Grenoble, France. ...
... an Anglo-American company has been allowed to store white ... by the US Food and Drug Administration. ... immune system that defend the body against both infectious ... take 480-millilitre of blood from interested healthy individuals and ...
... welcomed the European Union (EU) Parliament's resolution to ban mercury ... to do likewise. ,Toxics Link and other ... ,The group had called upon governments across the world to ... Programme (UNEP) in February. ,In one of ...
Cached Medicine News:Health News:Untreatable Eye Disease Improves With Avastin 2Health News:Researchers Devise New Compound to Treat Fungal Infections 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: